Verona Pharma plc — Director's Dealing 2025

May 5, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Verona Pharma plc (VRNA)
CIK: 0001657312
Period of Report: 2025-05-01

Reporting Person: EBSWORTH DAVID R (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-05-01	Ordinary Shares	M	140000	$1.9338	Acquired	1476003	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-05-01	Stock Option (Right to Exercise)	$1.9338	M	140000	Acquired	2034-04-28	Ordinary Shares (140000)	Direct

Footnotes

F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F2: Consists of (i) 1,476,000 Ordinary Shares represented by 184,500 ADSs and (ii) 3 Ordinary Shares.

F3: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F4: The option is fully vested.